NCT07872553 · Memorial Sloan Kettering Cancer Center
A Study of Treatment Delivery Preference In People With Kidney Cancer
What this study is about
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered given through a vein (IV) or injected under the skin and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
View original scientific description
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Interventions
DRUG
Nivolumab Injectable Product
Participants will be randomized to receive nivolumab subcutaneously
DRUG
Nivolumab
Participants will be randomized to receive Nivolumab intravenously
DRUG
Pembrolizumab injection
Participants will be randomized to receive Pembrolizumab subcutaneously
DRUG
Pembrolizumab
Participants will be randomized to receive Pembrolizumab intravenously
Primary outcome measures
Part I: Participants preference between intravenous/IV vs subcutaneous/SC immune checkpoint inhibitor (NIVO and PEMBRO) for Renal Cell Carcinoma.
Time frame: 1 year
The primary outcome is participants preference between the two formulations.
Part 2: Participant Preference between Standard of Care Delivery vs Labs at Home +Telehealth Visit
Time frame: 1 year
The primary outcome is participant preference between the two delivery models.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patients: A patient cannot be considered eligible for this study unless ALL of the following conditions are met.
- Patient is receiving standard of care treatment for renal cell carcinoma for one of the following indications: 1) NIVO monotherapy as maintenance, after ipilimumab and NIVO induction (up to 4 doses), 2) NIVO monotherapy as single-agent treatment, OR 3) adjuvant PEMBRO monotherapy or combination therapy with belzutifan. Of note, patient does not need to be newly initiating treatment to be eligible for this study.
- For patients on NIVO monotherapy or PEMBRO (Groups 2 and 3 above), they must have received at least 1 dose as a standard of care to be eligible
- Patient has at least 6 doses of planned treatment left as standard of care that can be given on protocol (either NIVO or PEMBRO)
- For example, standard of care for adjuvant PEMBRO is 1 year of therapy which can be given at 3 (17 doses) or 6 (9 doses) week intervals. Patients can enter this trial after starting treatment but must have at least 6 doses of treatment left to be eligible.
- For example, standard of care for maintenance NIVO (after ipilimumab + NIVO) is typically about 2 years of therapy. NIVO can be given at 2 (about 52 doses) or 4 week (about 26 doses) intervals.
- Ability to speak and read English because we do not have the resources to translate all materials into other languages
- Patient must be able to provide written informed consent, or a legal authorized representative (LAR)/caregiver must be identified to provide consent in cases where the patient cannot.
- Patients are unable to receive investigational agents on other clinical trial protocols Providers (Medical Oncologists):
- Medical oncologists in the genitourinary medical oncology department will be involved with this study if they are the treating investigator for patients who consent to this study
- The medical oncologists who are involved in this will be asked to complete surveys
Where
- Basking Ridge, New Jersey
- Middletown, New Jersey
- Montvale, New Jersey
- Commack, New York
- Harrison, New York
- New York, New York
- Uniondale, New York
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Oct 13, 2026 · Source of record for eligibility and locations